Galectin-3 Level in Ankylosing Spondylitis Patients

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ankylosing Spondylitis Ankylosis Arthritis Axial Spondyloarthritis Bone Diseases Joint Diseases Musculoskeletal Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis Spondylitis, Ankylosing

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Observational

About this study

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs.

We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ankylosing spondylitis patients
Healthy controls

Exclusion criteria

Hyperlipidemia
Liver diseases
Renal diseases
Hematological diseases
Familial thyroid diseases
Neoplastic diseases
Autoimmune infectious diseases
Receiving anti-inflammatory drugs.

Treatment and study plan

Serum galectin-3 concentration was measured.

Other

Serum galectin-3 concentration was measured using a commercial chemiluminescent microparticle immunoassay.

Primary outcomes

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

Time frame: 5 months

Correlation

Sponsors and collaborators

Lead sponsor

Recep Tayyip Erdogan University Training and Research Hospital

Other

Registry information

Official study title

Relationship Between Galectin-3 Level and Disease Activity in Ankylosing Spondylitis Patients

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2017
First posted: Feb 9, 2021
Registry last updated: Apr 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed